SCHEMBL1491235

SCHEMBL1491235

NC[C@H]1CCC(=O)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL864423 1.00
SCHEMBL864422 1.00
Hydrochloric Acid SCHEMBL22659576 0.98
Hydrochloric Acid SCHEMBL30098013 0.98 KCNA5 (0.34)
Hydrochloric Acid SCHEMBL20540318 0.98
Hydrochloric Acid SCHEMBL482332 0.98
Hydrochloric Acid SCHEMBL23250525 0.96
Oxalic Acid SCHEMBL30538366 0.90 ITGB1 (0.38)
SCHEMBL21673085 0.86
SCHEMBL23470493 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 US disclosed
WO-2024259171-A9 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-01-23 WO disclosed
US-20250011291-A1 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2025-01-09 US disclosed
WO-2024259171-A2 KEAP1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-12-19 WO disclosed
US-20240246964-A1 SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-25 US disclosed
WO-2024134466-A1 SUBSTITUTED ARYLAMINE COMPOUNDS, SUBSTITUTED HETEROARYLAMINE COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-06-27 WO disclosed
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses SHANGHAI AB PHARMATECH LTD. (CN) 2024-02-27 US disclosed
US-11912663-B2 Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses SHANGHAI AB PHARMATECH LTD. (CN) 2024-02-27 US disclosed
EP-4313968-A2 SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2024-02-07 EP disclosed
CN-117412959-A Substituted 1-aryl-1 '-heteroaryl compounds, substituted 1,1' -biaryl compounds, and methods of use thereof 爱彼特生物制药公司 2024-01-16 CN disclosed
EP-1485387-A1 CARBAMATES AS HIV PROTEASE INHIBITORS BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2004-12-15 EP disclosed
US-20040039016-A1 HIV protease inhibitors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-02-26 US disclosed
WO-2003078438-A1 CARBAMATES AS HIV PROTEASE INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2003-09-25 WO disclosed
EP-0678503-B1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities NOVARTIS AG (CH) 1999-09-01 EP disclosed
US-5705658-A HYPOTENSIVE AGENTS NOVARTIS CORPORATION (US) 1998-01-06 US disclosed
US-5654445-A INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-08-05 US disclosed
US-5646143-A FOR TREATING A VARIETY OF CONDITIONS CIBA-GEIGY CORPORATION (US) 1997-07-08 US disclosed
US-5627182-A RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS CIBA GEIGY CORPORATION (US) 1997-05-06 US disclosed
US-5559111-A HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren CIBA-GEIGY CORPORATION (US) 1996-09-24 US disclosed
EP-0678503-A1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities CIBA-GEIGY AG (CH) 1995-10-25 EP disclosed